Preticks
.
Follow Us
News Details
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
About Capricor Therapeutics, Inc.
NASDAQ: $CAPR
Notified: $9.00
07:01 EDT
Price Chart